BioMarin Pharmaceutical Details Strategy Refresh, Voxzogo Competition and 40% Margin Goal at TD Cowen Confab
“BioMarin Pharmaceutical’s leadership outlined a refreshed corporate strategy at the recent TD Cowen Healthcare Conference, focusing on business development, integration of recent acquisitions, and robust operational efficiencies. The company reaffirmed its target of approximately 40% non-GAAP operating margin in 2026 (excluding Amicus impact), while addressing emerging competition for its key growth driver Voxzogo and emphasizing … Read more